Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Article   |    
Association between mood-stabilizing medication and mental health resource use in the management of acute mania
Psychiatric Services 1997; doi:
text A A A
PDF of the full text article.


OBJECTIVE: To better understand how mood-stabilizing agents other than lithium have changed treatment and outcomes in bipolar disorder, this study examined health service utilization among patients with acute mania who were being treated with a variety of regimens using mood stabilizers. METHODS: Demographic, clinical, and resource utilization data were collected from the records of 96 inpatients with a discharge diagnosis of bipolar mania. Patients were categorized into four major treatment groups: lithium monotherapy, anticonvulsant monotherapy, treatment with multiple mood stabilizers, and treatment with no mood stabilizers. RESULTS: The mean +/- SD age of the sample was 50 +/- 12.3 years. Lithium was the most commonly prescribed antimanic agent, with 29 of the 96 patients on lithium monotherapy, 17 on anticonvulsant monotherapy, 42 taking multiple mood stabilizers, and eight taking no mood stabilizers. The mean inpatient stay was significantly longer for patients on multiple mood stabilizers (30.3 +/- 20.7 days) than for those on lithium monotherapy (20.7 +/- 14.4 days), anticonvulsant monotherapy (17 +/- 9.3 days), and no mood stabilizers (17.3 +/- 14.4 days). Patients who were not taking a mood stabilizer had a higher rate of leaving the hospital against medical advice than the other groups. Patients on anticonvulsant monotherapy had significantly more comorbid psychiatric illnesses than patients taking multiple mood stabilizers. Inpatient use of seclusion or restraint and of concurrent antipsychotic medications did not differ significantly between the treatment groups. Compliance with outpatient follow-up was poor in all treatment groups, and almost absent in the group taking no mood stabilizers. CONCLUSIONS: Changes in the pharmacological management of acute mania will have an impact on clinical outcomes and health resource utilization.

Abstract Teaser
Figures in this Article




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Web of Science® Times Cited: 7

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 10.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 5.  >
The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th Edition > Chapter 17.  >
Topic Collections
Psychiatric News
PubMed Articles